• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Abaloparatide protects against vertebral fractures in post-menopausal osteoporotic women

byQasim HussainiandMichael Milligan
September 6, 2016
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Abaloparatide significantly reduced the risk of new vertebral and non-vertebral fractures compared with placebo.

2. Treatment with abaloparatide also resulted in higher bone mineral density (BMD) gains compared with placebo and teriparatide.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Vertebral fractures disproportionately affect post-menopausal women, and lead to a lower quality of life and significant economic costs. Current treatments for osteoporosis include lifestyle modifications, adequate calcium and vitamin D intake, bisphosphonates, and hormonal therapy. The purpose of this study was to evaluate the efficacy of abaloparatide, a selective agonist of the parathyroid hormone type 1 receptor, on reducing vertebral and non-vertebral fractures in post-menopausal women with osteoporosis.

Patients taking abaloparatide had a significantly lower risk of developing new vertebral and non-vertebral fractures than those given placebo. The treatment group also had significant gains in bone mineral density (BMD) at the femoral neck, total hip, and lumbar spine compared to placebo. The risk of hypercalcemia was lower in the abaloparatide group compared with those taking open-label teriparatide, possibly indicating that abaloparatide results in less bone resorption.

Overall, this study suggests that use of abaloparatide reduces the risk of vertebral and non-vertebral fractures in post-menopausal osteoporotic women. However, the majority of study participants had a prior fracture, and it is not easily understood whether abaloparatide could have a similar benefit profile in patients with a lower risk of fracture.

RELATED REPORTS

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

Click to read the study in JAMA

Relevant Reading: Clinician’s guide to prevention and treatment of osteoporosis

In-Depth [randomized controlled trial]: This study was conducted as a subgroup analysis within the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) randomized clinical trial. In this phase 3, double-blind RCT, 2463 women (mean age 69 years) were randomized to receive 18 months of daily subcutaneous injections of abaloparatide 80 µg (n = 824), placebo (n = 821), or open-label teriparatide 20 µg (n = 818). A significant reduction in the primary outcome of new vertebral fractures was observed with abaloparatide compared to placebo (risk difference -3.64; 95%CI -5.42 to -2.10; p < 0.001). Bone mineral density gains were significant with abaloparatide vs. placebo at 6, 12, and 18 months (all p < 0.001), and risk of hypercalcemia also lower with abaloparatide vs. teriparatide (RD -2.96; 95%CI -5.12 to -0.87). Mild to moderate adverse events leading to study discontinuation occurred more frequently in the abaloparatide group, while serious events occurred at similar levels in the abaloparatide and teriparatide groups.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: osteoporosis
Previous Post

PCSK9 inhibitors unlikely to be cost-effective

Next Post

Obeticholic acid associated with improved PBC biomarker trends compared to ursodiol: The POISE trial

RelatedReports

Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
StudyGraphics

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

January 22, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Nephrology

Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease

November 18, 2024
Next Post
Increasing survival rates for patients with acute liver failure

Obeticholic acid associated with improved PBC biomarker trends compared to ursodiol: The POISE trial

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

2 Minute Medicine Rewind August 15, 2016

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Non-invasive bladder stimulation effective to obtain urine samples in infants

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.